After months of speculation about a possible takeover of Mirati Therapeutics, Bristol-Myers Squibb has reached a deal to buy the company and its KRAS inhibitor Krazati in a deal valued at up to $5 ...
Amgen has its first direct competition in the KRAS inhibitor class following FDA approval of Mirati's adagrasib as Krazati for a form of lung cancer. Krazati has been cleared as a treatment for ...
Hosted on MSN11mon
Zai Lab reports Krazati lung cancer study meets primary endpointBristol Myers acquired Krazati through its takeover of the drug’s developer Mirati earlier this year. Zai obtained exclusive rights to commercialize Krazati in China from Mirati in 2021 ...
Dealbreaker on MSN9d
BridgeBio Oncology to Go Public in SPAC Deal Bringing $450 Million-Plus for Trio of Cancer DrugsClinical-stage BridgeBio Oncology Therapeutics, whose financial backers include Cormorant Asset Management, is going public ...
Dr. Nataliya Uboha explained the benefit of treatment with Krazati combined with Erbitux in KRAS G12C–mutant metastatic colorectal cancer. Among patients with heavily pretreated patients with KRAS ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback